These targets demonstrate great potential in immunotherapy, and the overexpression of immune-oncology-related genes such as NFSF14, LY96, SLC11A1, and CTSL is associated with shorter survival in glioblastoma patients, serving as stratification indicators for immunotherapy or chemotherapy in glioma patients [42]. This evidence concerns the gene SLC11A1 and glioblastoma.